Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 236 entries
Sorted by: Best Match Show Resources per page
Effects of the modified electric convulsive treatment (MECT) on cell factors of schizophrenia.

Experimental and therapeutic medicine

Guo YF, Fu HB, Liu ZY, Lu W, Luo KY, Zhu HR, Ning WD, Chen F, Yang LY, Zhou XD.
PMID: 28450912
Exp Ther Med. 2017 Mar;13(3):873-876. doi: 10.3892/etm.2017.4075. Epub 2017 Jan 20.

The expression of cell factors of schizophrenia and the effect of the modified electric convulsive treatment (MECT) were studied. In total, 156 patients with schizophrenia were selected, and divided into the drug group (70 cases) and the drug combined...

Cite
Guo YF, Fu HB, Liu ZY, et al. Effects of the modified electric convulsive treatment (MECT) on cell factors of schizophrenia. Exp Ther Med. 2017;13(3):873-876doi: 10.3892/etm.2017.4075.
Guo, Y. F., Fu, H. B., Liu, Z. Y., Lu, W., Luo, K. Y., Zhu, H. R., Ning, W. D., Chen, F., Yang, L. Y., & Zhou, X. D. (2017). Effects of the modified electric convulsive treatment (MECT) on cell factors of schizophrenia. Experimental and therapeutic medicine, 13(3), 873-876. https://doi.org/10.3892/etm.2017.4075
Guo, Yong-Fang, et al. "Effects of the modified electric convulsive treatment (MECT) on cell factors of schizophrenia." Experimental and therapeutic medicine vol. 13,3 (2017): 873-876. doi: https://doi.org/10.3892/etm.2017.4075
Guo YF, Fu HB, Liu ZY, Lu W, Luo KY, Zhu HR, Ning WD, Chen F, Yang LY, Zhou XD. Effects of the modified electric convulsive treatment (MECT) on cell factors of schizophrenia. Exp Ther Med. 2017 Mar;13(3):873-876. doi: 10.3892/etm.2017.4075. Epub 2017 Jan 20. PMID: 28450912; PMCID: PMC5403391.
Copy Download .nbib Format: NLM
Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review.

Neuropsychiatric disease and treatment

Zhang L, Li J, Zhao Y, Su Y, Si T.
PMID: 26811684
Neuropsychiatr Dis Treat. 2016 Jan 11;12:113-31. doi: 10.2147/NDT.S64672. eCollection 2016.

BACKGROUND: Paliperidone (9-hydroxyrisperidone), the major active metabolite of risperidone, has been introduced as a novel atypical antipsychotic agent in many countries. It is available both as an oral extended-release (ER) formulation and as a long-acting injection (paliperidone palmitate, PP),...

Cite
Zhang L, Li J, Zhao Y, et al. Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review. Neuropsychiatr Dis Treat. 2016;12:113-31doi: 10.2147/NDT.S64672.
Zhang, L., Li, J., Zhao, Y., Su, Y., & Si, T. (2016). Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review. Neuropsychiatric disease and treatment, 12113-31. https://doi.org/10.2147/NDT.S64672
Zhang, LiLi, et al. "Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review." Neuropsychiatric disease and treatment vol. 12 (2016): 113-31. doi: https://doi.org/10.2147/NDT.S64672
Zhang L, Li J, Zhao Y, Su Y, Si T. Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review. Neuropsychiatr Dis Treat. 2016 Jan 11;12:113-31. doi: 10.2147/NDT.S64672. eCollection 2016. PMID: 26811684; PMCID: PMC4714741.
Copy Download .nbib Format: NLM
Treatment resistant non-catatonic mutism in schizophrenia responding to a combination of continuation electroconvulsive therapy and neuroleptics.

Industrial psychiatry journal

Grover S, Dutt A, Chakrabarty K, Kumar V.
PMID: 23766583
Ind Psychiatry J. 2012 Jan;21(1):69-71. doi: 10.4103/0972-6748.110957.

Non-catatonic mutism in schizophrenia has been described less frequently in literature. We describe the case of a young male who presented with non-catatonic mutism, secondary to first rank symptoms, which was refractory to adequate antipsychotic trials (quetiapine, risperidone, aripiprazole,...

Cite
Grover S, Dutt A, Chakrabarty K, et al. Treatment resistant non-catatonic mutism in schizophrenia responding to a combination of continuation electroconvulsive therapy and neuroleptics. Ind Psychiatry J. 2012;21(1):69-71doi: 10.4103/0972-6748.110957.
Grover, S., Dutt, A., Chakrabarty, K., & Kumar, V. (2012). Treatment resistant non-catatonic mutism in schizophrenia responding to a combination of continuation electroconvulsive therapy and neuroleptics. Industrial psychiatry journal, 21(1), 69-71. https://doi.org/10.4103/0972-6748.110957
Grover, Sandeep, et al. "Treatment resistant non-catatonic mutism in schizophrenia responding to a combination of continuation electroconvulsive therapy and neuroleptics." Industrial psychiatry journal vol. 21,1 (2012): 69-71. doi: https://doi.org/10.4103/0972-6748.110957
Grover S, Dutt A, Chakrabarty K, Kumar V. Treatment resistant non-catatonic mutism in schizophrenia responding to a combination of continuation electroconvulsive therapy and neuroleptics. Ind Psychiatry J. 2012 Jan;21(1):69-71. doi: 10.4103/0972-6748.110957. PMID: 23766583; PMCID: PMC3678184.
Copy Download .nbib Format: NLM
The impact of weight gain associated with atypical antipsychotic use in schizophrenia.

Acta neuropsychiatrica

Chue P, Cheung R.
PMID: 26984162
Acta Neuropsychiatr. 2004 Jun;16(3):113-23. doi: 10.1111/j.0924-2708.2004.00067.x.

BACKGROUND: Atypical antipsychotics offer clear advantages in the management of schizophrenia, compared with conventional neuroleptics, but weight gain is a significant adverse effect with some of these agents.OBJECTIVE: To review the literature on weight gain associated with atypical antipsychotic...

Cite
Chue P, Cheung R. The impact of weight gain associated with atypical antipsychotic use in schizophrenia. Acta Neuropsychiatr. 2004;16(3):113-23doi: 10.1111/j.0924-2708.2004.00067.x.
Chue, P., & Cheung, R. (2004). The impact of weight gain associated with atypical antipsychotic use in schizophrenia. Acta neuropsychiatrica, 16(3), 113-23. https://doi.org/10.1111/j.0924-2708.2004.00067.x
Chue, Pierre, and Cheung, Raphael. "The impact of weight gain associated with atypical antipsychotic use in schizophrenia." Acta neuropsychiatrica vol. 16,3 (2004): 113-23. doi: https://doi.org/10.1111/j.0924-2708.2004.00067.x
Chue P, Cheung R. The impact of weight gain associated with atypical antipsychotic use in schizophrenia. Acta Neuropsychiatr. 2004 Jun;16(3):113-23. doi: 10.1111/j.0924-2708.2004.00067.x. PMID: 26984162.
Copy Download .nbib Format: NLM
Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease.

American journal of neurodegenerative disease

Lauterbach EC.
PMID: 27073741
Am J Neurodegener Dis. 2016 Mar 01;5(1):29-51. eCollection 2016.

Anxiety is common in the Mild Cognitive Impairment (MCI) stage of Alzheimer's disease (AD) and the pre-motor stages of Parkinson's disease (PD). A concomitant and possible cause of this anxiety is microglial activation, also considered a key promoter of...

Cite
Lauterbach EC. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. Am J Neurodegener Dis. 2016;5(1):29-51
Lauterbach, E. C. (2016). Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. American journal of neurodegenerative disease, 5(1), 29-51.
Lauterbach, Edward C. "Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease." American journal of neurodegenerative disease vol. 5,1 (2016): 29-51.
Lauterbach EC. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. Am J Neurodegener Dis. 2016 Mar 01;5(1):29-51. eCollection 2016. PMID: 27073741; PMCID: PMC4788730.
Copy Download .nbib Format: NLM
Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013.

Israel journal of health policy research

Ponizovsky AM, Marom E, Ben-Laish M, Barash I, Weizman A, Schwartzberg E.
PMID: 27307984
Isr J Health Policy Res. 2016 Jun 15;5:16. doi: 10.1186/s13584-016-0074-7. eCollection 2016.

BACKGROUND: Although serious mental illneses are treated with both typical and atypical antipsychotic grugs, trends in their use in psychiatric inpatient population in Israel are unrecognized. The aim of this study was to detect trends in the use of...

Cite
Ponizovsky AM, Marom E, Ben-Laish M, et al. Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013. Isr J Health Policy Res. 2016;5:16doi: 10.1186/s13584-016-0074-7.
Ponizovsky, A. M., Marom, E., Ben-Laish, M., Barash, I., Weizman, A., & Schwartzberg, E. (2016). Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013. Israel journal of health policy research, 516. https://doi.org/10.1186/s13584-016-0074-7
Ponizovsky, Alexander M, et al. "Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013." Israel journal of health policy research vol. 5 (2016): 16. doi: https://doi.org/10.1186/s13584-016-0074-7
Ponizovsky AM, Marom E, Ben-Laish M, Barash I, Weizman A, Schwartzberg E. Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013. Isr J Health Policy Res. 2016 Jun 15;5:16. doi: 10.1186/s13584-016-0074-7. eCollection 2016. PMID: 27307984; PMCID: PMC4908675.
Copy Download .nbib Format: NLM
A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice.

Neuropsychiatric disease and treatment

Bodén R, Edman G, Reutfors J, Ostenson CG, Osby U.
PMID: 23682213
Neuropsychiatr Dis Treat. 2013;9:371-7. doi: 10.2147/NDT.S40554. Epub 2013 Mar 19.

It is well known that abdominal obesity, dyslipidemia, and insulin resistance are highly prevalent in patients receiving maintenance treatment with antipsychotics, but there is limited knowledge about the association between cardiovascular risk factors and treatment with antipsychotic drugs. In...

Cite
Bodén R, Edman G, Reutfors J, et al. A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice. Neuropsychiatr Dis Treat. 2013;9:371-7doi: 10.2147/NDT.S40554.
Bodén, R., Edman, G., Reutfors, J., Ostenson, C. G., & Osby, U. (2013). A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice. Neuropsychiatric disease and treatment, 9371-7. https://doi.org/10.2147/NDT.S40554
Bodén, Robert, et al. "A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice." Neuropsychiatric disease and treatment vol. 9 (2013): 371-7. doi: https://doi.org/10.2147/NDT.S40554
Bodén R, Edman G, Reutfors J, Ostenson CG, Osby U. A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice. Neuropsychiatr Dis Treat. 2013;9:371-7. doi: 10.2147/NDT.S40554. Epub 2013 Mar 19. PMID: 23682213; PMCID: PMC3653763.
Copy Download .nbib Format: NLM
Atypical antipsychotics in the treatment of early-onset schizophrenia.

Neuropsychiatric disease and treatment

Hrdlicka M, Dudova I.
PMID: 25897226
Neuropsychiatr Dis Treat. 2015 Apr 01;11:907-13. doi: 10.2147/NDT.S82185. eCollection 2015.

Atypical antipsychotics (AAPs) have been successfully used in early-onset schizophrenia (EOS). This review summarizes the randomized, double-blind, controlled studies of AAPs in EOS, including clozapine, risperidone, olanzapine, aripiprazole, paliperidone, quetiapine, and ziprasidone. No significant differences in efficacy between AAPs...

Cite
Hrdlicka M, Dudova I. Atypical antipsychotics in the treatment of early-onset schizophrenia. Neuropsychiatr Dis Treat. 2015;11:907-13doi: 10.2147/NDT.S82185.
Hrdlicka, M., & Dudova, I. (2015). Atypical antipsychotics in the treatment of early-onset schizophrenia. Neuropsychiatric disease and treatment, 11907-13. https://doi.org/10.2147/NDT.S82185
Hrdlicka, Michal, and Dudova, Iva. "Atypical antipsychotics in the treatment of early-onset schizophrenia." Neuropsychiatric disease and treatment vol. 11 (2015): 907-13. doi: https://doi.org/10.2147/NDT.S82185
Hrdlicka M, Dudova I. Atypical antipsychotics in the treatment of early-onset schizophrenia. Neuropsychiatr Dis Treat. 2015 Apr 01;11:907-13. doi: 10.2147/NDT.S82185. eCollection 2015. PMID: 25897226; PMCID: PMC4389913.
Copy Download .nbib Format: NLM
The new generation of antipsychotic drugs: how atypical are they?.

The international journal of neuropsychopharmacology

Goldstein JM.
PMID: 11343614
Int J Neuropsychopharmacol. 2000 Dec;3(4):339-349. doi: 10.1017/S1461145700002042.

The cardinal feature of traditional neuroleptic drugs is extrapyramidal symptoms (EPS), such as parkinsonism, akathisia, and dystonia. Irrespective of the autonomic nervous system side-effect profile of a specific neuroleptic, the entire class produces EPS. Therefore, EPS and antipsychotic activity...

Cite
Goldstein JM. The new generation of antipsychotic drugs: how atypical are they?. Int J Neuropsychopharmacol. 2000;3(4):339-349doi: 10.1017/S1461145700002042.
Goldstein, J. M. (2000). The new generation of antipsychotic drugs: how atypical are they?. The international journal of neuropsychopharmacology, 3(4), 339-349. https://doi.org/10.1017/S1461145700002042
Goldstein, Jeffrey M.. "The new generation of antipsychotic drugs: how atypical are they?." The international journal of neuropsychopharmacology vol. 3,4 (2000): 339-349. doi: https://doi.org/10.1017/S1461145700002042
Goldstein JM. The new generation of antipsychotic drugs: how atypical are they?. Int J Neuropsychopharmacol. 2000 Dec;3(4):339-349. doi: 10.1017/S1461145700002042. PMID: 11343614.
Copy Download .nbib Format: NLM
Efficacy and safety of novel antipsychotics: a critical review.

Human psychopharmacology

Balestrieri M, Vampini C, Bellantuono C.
PMID: 12404619
Hum Psychopharmacol. 2000 Oct;15(7):499-512. doi: 10.1002/1099-1077(200010)15:7<499::AID-HUP194>3.0.CO;2-3.

Efficacy and safety of novel antipsychotic (AP) drugs (amisulpride, olanzapine, quetiapine, ziprasidone and zotepine) have been reviewed. Data on their antipsychotic efficacy and side effects profile have been evaluated only on the basis of controlled trials so far published....

Cite
Balestrieri M, Vampini C, Bellantuono C. Efficacy and safety of novel antipsychotics: a critical review. Hum Psychopharmacol. 2000;15(7):499-512doi: 10.1002/1099-1077(200010)15:7<499::AID-HUP194>3.0.CO;2-3.
Balestrieri, M., Vampini, C., & Bellantuono, C. (2000). Efficacy and safety of novel antipsychotics: a critical review. Human psychopharmacology, 15(7), 499-512. https://doi.org/10.1002/1099-1077(200010)15:7<499::AID-HUP194>3.0.CO;2-3
Balestrieri, Matteo, et al. "Efficacy and safety of novel antipsychotics: a critical review." Human psychopharmacology vol. 15,7 (2000): 499-512. doi: https://doi.org/10.1002/1099-1077(200010)15:7<499::AID-HUP194>3.0.CO;2-3
Balestrieri M, Vampini C, Bellantuono C. Efficacy and safety of novel antipsychotics: a critical review. Hum Psychopharmacol. 2000 Oct;15(7):499-512. doi: 10.1002/1099-1077(200010)15:7<499::AID-HUP194>3.0.CO;2-3. PMID: 12404619.
Copy Download .nbib Format: NLM
Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia.

Evidence-based mental health

Taylor D.
PMID: 17652558
Evid Based Ment Health. 2007 Aug;10(3):76. doi: 10.1136/ebmh.10.3.76.

No abstract available.

Cite
Taylor D. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evid Based Ment Health. 2007;10(3):76doi: 10.1136/ebmh.10.3.76.
Taylor, D. (2007). Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evidence-based mental health, 10(3), 76. https://doi.org/10.1136/ebmh.10.3.76
Taylor, David. "Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia." Evidence-based mental health vol. 10,3 (2007): 76. doi: https://doi.org/10.1136/ebmh.10.3.76
Taylor D. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evid Based Ment Health. 2007 Aug;10(3):76. doi: 10.1136/ebmh.10.3.76. PMID: 17652558.
Copy Download .nbib Format: NLM
Atypical antipsychotics: sleep, sedation, and efficacy.

Primary care companion to the Journal of clinical psychiatry

Miller DD.
PMID: 16001094
Prim Care Companion J Clin Psychiatry. 2004;6:3-7.

Patients with schizophrenia often suffer from sleep disturbances such as excessive sleeping and insomnia. Common medications for schizophrenia can have a sedative effect on patients. Not all antipsychotic medications have the same sedative effect, which is related to dosage...

Cite
Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry. 2004;6:3-7
Miller, D. D. (2004). Atypical antipsychotics: sleep, sedation, and efficacy. Primary care companion to the Journal of clinical psychiatry, 63-7.
Miller, Del D. "Atypical antipsychotics: sleep, sedation, and efficacy." Primary care companion to the Journal of clinical psychiatry vol. 6 (2004): 3-7.
Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry. 2004;6:3-7. PMID: 16001094; PMCID: PMC487011.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 236 entries